Marina Sagud1,2, Matea Nikolac Perkovic3, Anja Dvojkovic4, Nenad Jaksic1, Bjanka Vuksan-Cusa1,2, Maja Zivkovic1,2, Zorana Kusevic1,2, Alma Mihaljevic-Peles1,2, Nela Pivac5. 1. Department of Psychiatry and Psychological Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia. 2. School of Medicine, University of Zagreb, Salata 3, 10000, Zagreb, Croatia. 3. Rudjer Boskovic Institute, Bijenicka cesta 54, 10000, Zagreb, Croatia. 4. University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10090, Zagreb, Croatia. 5. Rudjer Boskovic Institute, Bijenicka cesta 54, 10000, Zagreb, Croatia. npivac@irb.hr.
Abstract
RATIONALE: Cognitive dysfunction is frequent in major depressive disorder (MDD), and brain-derived neurotrophic factor (BDNF) is involved both in regulation of cognition and in therapeutic response in MDD. OBJECTIVES: The aim of this study was to determine if baseline plasma BDNF might predict change in cognitive function in MDD patients treated with vortioxetine or escitalopram, and whether the alterations in BDNF levels correlate with changes in cognitive performance during treatment. METHODS: Drug-naive or drug-free patients with MDD (N=121) were sampled and evaluated at baseline and 4 weeks after treatment initiation with vortioxetine or escitalopram. Cognitive function was evaluated using the F-A-S test, Digit Span test, and Digit Symbol Coding test. Plasma BDNF was determined using ELISA. RESULTS: The results of the study indicate that both vortioxetine (V) and escitalopram (E) improved cognitive functions evaluated with F-A-S test (V: p<0.001; r=-0.427, E: p<0.001; r=-0.370), Digit Symbol Coding test (V: p<0.001; r=-0.706, E: p<0.001; r=-0.435), and Digit Span test-backward span (V: p=0.001; r=-0.311, E: p=0.042; r=-0.185), while only vortioxetine (p<0.001; r=-0.325) improved cognition evaluated with the Digit Span test-forward span. A moderate positive correlation between pretreatment plasma BDNF levels and improvement in cognitive performance was only detected in patients treated with vortioxetine (delta F-A-S test: p=0.011; r=0.325, delta Digit Span test-forward span: p=0.010, r=0.326). CONCLUSIONS: These results suggest that higher baseline plasma BDNF levels might be associated with improvements in verbal fluency and working memory in vortioxetine, but not escitalopram treated patients. Vortioxetine treatment was superior in simple attention efficiency.
RATIONALE: Cognitive dysfunction is frequent in major depressive disorder (MDD), and brain-derived neurotrophic factor (BDNF) is involved both in regulation of cognition and in therapeutic response in MDD. OBJECTIVES: The aim of this study was to determine if baseline plasma BDNF might predict change in cognitive function in MDDpatients treated with vortioxetine or escitalopram, and whether the alterations in BDNF levels correlate with changes in cognitive performance during treatment. METHODS: Drug-naive or drug-free patients with MDD (N=121) were sampled and evaluated at baseline and 4 weeks after treatment initiation with vortioxetine or escitalopram. Cognitive function was evaluated using the F-A-S test, Digit Span test, and Digit Symbol Coding test. Plasma BDNF was determined using ELISA. RESULTS: The results of the study indicate that both vortioxetine (V) and escitalopram (E) improved cognitive functions evaluated with F-A-S test (V: p<0.001; r=-0.427, E: p<0.001; r=-0.370), Digit Symbol Coding test (V: p<0.001; r=-0.706, E: p<0.001; r=-0.435), and Digit Span test-backward span (V: p=0.001; r=-0.311, E: p=0.042; r=-0.185), while only vortioxetine (p<0.001; r=-0.325) improved cognition evaluated with the Digit Span test-forward span. A moderate positive correlation between pretreatment plasma BDNF levels and improvement in cognitive performance was only detected in patients treated with vortioxetine (delta F-A-S test: p=0.011; r=0.325, delta Digit Span test-forward span: p=0.010, r=0.326). CONCLUSIONS: These results suggest that higher baseline plasma BDNF levels might be associated with improvements in verbal fluency and working memory in vortioxetine, but not escitalopram treated patients. Vortioxetine treatment was superior in simple attention efficiency.
Authors: S Begliuomini; E Casarosa; N Pluchino; E Lenzi; M Centofanti; L Freschi; M Pieri; A D Genazzani; S Luisi; Andrea R Genazzani Journal: Hum Reprod Date: 2007-01-24 Impact factor: 6.918
Authors: Breno S Diniz; Antonio L Teixeira; Rodrigo Machado-Vieira; Leda L Talib; Marcia Radanovic; Wagner F Gattaz; Orestes V Forlenza Journal: J Gerontol B Psychol Sci Soc Sci Date: 2014-08-22 Impact factor: 4.077
Authors: Kevin Duff; Leigh J Beglinger; Susan K Schultz; David J Moser; Robert J McCaffrey; Richard F Haase; Holly J K Westervelt; Douglas R Langbehn; Jane S Paulsen Journal: Arch Clin Neuropsychol Date: 2006-12-04 Impact factor: 2.813
Authors: Sanjay Dubé; Mary Anne Dellva; Marcia Jones; William Kielbasa; Robert Padich; Amitabh Saha; Prasad Rao Journal: J Psychiatr Res Date: 2009-11-11 Impact factor: 4.791
Authors: Ira Driscoll; Bronwen Martin; Yang An; Stuart Maudsley; Luigi Ferrucci; Mark P Mattson; Susan M Resnick Journal: PLoS One Date: 2012-04-16 Impact factor: 3.240